Oragenics (OGEN) provided an update on its strategic progress since its last capital raise in September 2024. The Company also announced the appointment of Janet Huffman as its new interim Chief Executive Officer. Following the Company’s $4 million capital raise in September 2024, the Company has made significant advancements, including: Formulation and Device Enhancements; Advancing Phase II Preparations; Supply Chain Preparedness; Prototyping for Enhanced Accessibility; Regulatory Milestones
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio